AbbVie's New Hep C Drug Will Break Gilead's Dominance If Approved In EU

 
• By Lucie Ellis-Taitt

AbbVie and Gilead's latest hepatitis C therapies are anticipated to win positive recommendations for approval in Europe this week – but AbbVie's drug is the one to watch as analysts have dubbed it a potential blockbuster.

Hepatitis C
AbbVie's Hep C Combo Is Likely To Win CHMP Nod This Week; A New Threat To Gilead's Rule

More from Anti-infective

More from Therapy Areas